Wearable Injectors and Connected Devices Conference 2019

SMi Group9 - 10 October 2019, London, UK.
SMi is proud to present the inaugural Wearable Injectors and Connected Devices Conference, taking place in London. The global wearable devices market size is expected to reach a value of $12.1 billion USD by 2021 with time dependent delivery, large volume administration with minimal injection pain and the use of connectivity to enhance user-value being key factors driving the market.

With this in mind, the conference will explore new technologies and advances of on-body devices for the administration of viscous and large molecule drug delivery, and evaluate the impact of IoT, connectivity and enhancement of user-interface, which make up core components within the wearable devices field.

Benefits of Attending

  • Listen to case studies from leading pharmaceutical companies revolutionising the medical device industry
  • Hear how on-body injectors are facilitating the administration of time-dependent, large volume and viscous drug delivery
  • Assess how connectivity is being used to improve patient adherence, health-monitoring and enhancing the user-interface
  • Explore the compatibility, pain and patient handling considerations projecting wearable devices as the future of drug delivery

Join Wearable Injectors and Connected Devices Conference 2019 in October 2019 to have the opportunity to network with Global Device Development Managers, Senior Connectivity Engineers, Leaders in Device Data Generation, Human Factors Directors and many more.

Plus two interactive pre-conference workshops

Tuesday 8th October 2019

Cross company collaboration to develop digital therapeutic solutions using connected devices

Workshop Leader: Digby Harris, Global Category Manager - Digital Therapeutics & Devices, AstraZeneca

Wearable injectors: Envisioning their evolution to address current and future unmet needs

Workshop Leader: James Blakemore, Senior Consultant, Cambridge Consultants
Workshop Leader: Sergio Marlorni, Senior Consultant, Cambridge Consultants

Who should attend?

Executives, Directors, VPs, Heads, Principals, Managers of: Drug-delivery developers, Autoinjectors, Device Engineering, Human Factor, Scientist, Product, Injectables, Packaging, Regulatory Affairs, Connectivity, Medical Device Data, Novel Product Technology, Smart device developers, Training device developers, Device-safety solution providers, Drug developers or anyone who works with Wearable Devices/ On-Body Injectors within pharmaceutical, biotech and solution providers.

To register please visit: www.wearable-injectors.co.uk/wpnwl

Early-Bird Rates

  • Book by 31st May and save £400
  • Book by 28th June and save £300
  • Book by 30th August and save £200

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...